Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 20:10:179-182.
doi: 10.1016/j.ijregi.2024.01.007. eCollection 2024 Mar.

Pre-vaccination seroprevalence of SARS-CoV-2 antibodies in the Volta Region, Ghana

Affiliations

Pre-vaccination seroprevalence of SARS-CoV-2 antibodies in the Volta Region, Ghana

Enoch Aninagyei et al. IJID Reg. .

Abstract

Objectives: Before administration of the first dose of the AstraZeneca 2019 SARS-CoV-2 vaccine to selected prioritized groups in the Volta regional capital of Ghana, we determined the pre-vaccination status of prospective recipients and established the baseline exposure status 1 year after the first case was reported.

Methods: After informed consent, blood samples were collected for the detection of SARS-CoV-2 immunoglobulin (Ig) M/IgG antibodies using rapid diagnostic test kits. A total of 409 individuals (mean age 27 years) consented and participated in the study, comprising 70% students and others were health staff and educators who presented themselves for vaccination.

Results: The overall exposure rate of SARS-CoV-2 was 12.7% (95% confidence interval [CI] 9.6-16.3). The prevalence of SARS-CoV-2 IgM and IgG were 4.2% (95% CI 2.4-6.6) and 5.6% (95% CI 3.6-8.3), respectively. IgM and IgG were detected in 2.9% (95% CI 1.5-5.1) of the respondents. The exposure rates were higher in participants over 40 years old (15.5%). Participants without a history of COVID-19-like symptoms had an exposure rate of 13.0% and those without any chronic diseases was 13.2%.

Conclusion: Pre-vaccination exposure was relatively low and underscored the need for vaccination i to increase protection in communities and disease outcomes.

Keywords: COVID-19; Exposure; Pandemic; SARS-CoV-2; Vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interest to declare.

Similar articles

Cited by

  • Population-based cross-sectional seroprevalence study of SARS-CoV-2 infection in urban residential areas in Ghana.
    Amuasi JH, Afum-Adjei Awuah A, Obirikorang C, Adu EA, Boham EEA, Boakye AO, Alani H, Newton S, Almoustapha NS, Deke J, Dzadey WO, Adu-Amoah L, Kroduah SA, Grant MA, Asare G, Amoako-Adusei A, Loag W, Kettenbeil J, Adu Sarkodie Y, Oduro E, Yawson AE, Apanga S, Odotei Adjei R, Adobasom Anane AG, Lorenz E, Souares A, Maiga Ascofare O, Jurgen M, Struck NS. Amuasi JH, et al. BMJ Public Health. 2025 Jun 23;3(1):e001994. doi: 10.1136/bmjph-2024-001994. eCollection 2025. BMJ Public Health. 2025. PMID: 40557286 Free PMC article.

References

    1. World Health Organization . 2023. Coronavirus disease (COVID-19) pandemic.https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [accessed 30 September 2023] - PubMed
    1. Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. Glob Health Res Policy. 2020;5:6. doi: 10.1186/s41256-020-00135-6. - DOI - PMC - PubMed
    1. Ghana Health Service . 2023. Ghana's outbreak response management updates Accra: Ghana Health Service.https://www.ghs.gov.gh/covid19/ [accessed 30 September 2023]
    1. Apanga PA, Kumbeni MT. Adherence to COVID-19 preventive measures and associated factors among pregnant women in Ghana. Trop Med Int Health. 2021;26:656–663. doi: 10.1111/tmi.13566. - DOI - PMC - PubMed
    1. Bonful HA, Addo-Lartey A, Aheto JMK, Ganle JK, Sarfo B, Aryeetey R. Limiting spread of COVID-19 in Ghana: compliance audit of selected transportation stations in the Greater Accra region of Ghana. PLoS One. 2020;15 doi: 10.1371/journal.pone.0238971. - DOI - PMC - PubMed

LinkOut - more resources